“Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials”, J of Skin, vol. 6, no. 6, p. s45, Nov. 2022, doi: 10.25251/skin.6.supp.45.